Circulating Tumor Cell Dynamics after CDK4/6 Inhibitor for Hormone Receptor–Positive Metastatic Breast Cancer: A Biomarker Analysis from the PACE Phase II Study
Baseline CTC enumeration provides significant prognostic information in HR+/HER2- MBC. Stage IVaggressive patients derive greater benefit from F + P or F + P + A over fulvestrant alone, independent of clinical or ctDNA features. This highlights the potential of CTCs to guide treatment decision-making.
Authors
- Yara George Abdou (ORCID: https://orcid.org/0000-0002-4827-8613)
- Reshma Mahtani (ORCID: https://orcid.org/0000-0002-7711-8627)
- Angela M. DeMichele (ORCID: https://orcid.org/0000-0003-1297-4251)
- Yue Ren (ORCID: https://orcid.org/0009-0003-4777-3342)
- Meredith M. Regan (ORCID: https://orcid.org/0000-0002-2428-6109)
- Massimo Cristofanilli (ORCID: https://orcid.org/0000-0002-4194-7175)
- Sonya Reid (ORCID: https://orcid.org/0000-0003-3787-5233)
- Cynthia X. Ma (ORCID: https://orcid.org/0000-0002-8156-7492)
- Priyanka Sharma (ORCID: https://orcid.org/0000-0001-8592-2239)
- Rinath M. Jeselsohn (ORCID: https://orcid.org/0000-0001-7996-7529)
- Lorenzo Gerratana (ORCID: https://orcid.org/0000-0002-8313-4834)
- Harold J. Burstein (ORCID: https://orcid.org/0000-0003-1963-8162)
- Carolina Reduzzi (ORCID: https://orcid.org/0000-0003-0514-0152)
- Kathy D. Miller (ORCID: https://orcid.org/0000-0002-7125-883X)
- Sara M. Tolaney (ORCID: https://orcid.org/0000-0002-5940-8671)
- Naomi Y. Ko (ORCID: https://orcid.org/0000-0001-9689-9601)
- Erica L. Mayer (ORCID: https://orcid.org/0000-0001-5430-8957)
- Jane Meisel (ORCID: https://orcid.org/0000-0002-2642-865X)
- Yuan Liu (ORCID: https://orcid.org/0000-0002-2728-5718)
- Eric Gauthier (ORCID: https://orcid.org/0000-0002-0160-7571)
- Elizabeth C. Riley (ORCID: https://orcid.org/0000-0002-3923-7684)
- Michelle K. DeMeo
- Rubina Qamar (ORCID: https://orcid.org/0009-0002-2069-1163)
Institutions
- Boston University (US)
- University of North Carolina at Chapel Hill (US)
- Indiana University Health (US)
- Boston Medical Center (US)
- University of Udine (IT)
- Baptist Hospital of Miami (US)
- Harvard University (US)
- University of Louisville (US)
- Emory University (US)
- Pfizer (United States) (US)
- Washington University in St. Louis (US)
- Cornell University (US)
- Society for Immunotherapy of Cancer (US)
- Baptist Health South Florida (US)
- Piedmont Cancer Institute (US)
- La Jolla Alcohol Research (US)
- Indiana Cancer Consortium (US)
- Dana-Farber Cancer Institute (US)
- National Cancer Institute (UA)
- University of Kansas Medical Center (US)
- University of Colorado Cancer Center (US)
- Miami Transplant Institute (US)
- Cancer Institute of Florida (US)
- Weill Cornell Medicine (US)
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
- University of Pennsylvania (US)
- Vanderbilt University Medical Center (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-08-25
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-0327
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00